25 July 2019
Russian pharmaceutical company NovaMedica and US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen®, a drug that improves the sleep/wake cycle. Volumes are expected to reach hundreds of thousands of units per year, which will be sufficient to fully meet the needs of patients living in the territory of the EAEU.
17 June 2019
Russian pharmaceutical companies NovaMedica and Pharmsynthez started implementing a joint project to ensure access to a number of effective products, with the full manufacturing cycle localized in Russia, for Russian patients within 1.5-2 years. The products are in the anesthesiology and gastroenterology therapeutic areas, intended for both the hospital and commercial markets.
09 October 2018
The international exhibition CPhI has started in Madrid. And today NovaMedica Innotech is in our focus as the company that has made a bright debut at the exhibition. This Technological Center has launched in April 2017 and Moscow Mayor Sergei Sobyanin attended the opening ceremony.
25 September 2018
In 2018 Alexander Kuzin, General Director of NovaMedica, was ranked among the most recognized senior managers in the pharmaceutical industry for the fifth time in the rating list. Maria Makarova, Deputy General Director and Vice-President for Finance; Marina Aivazova, Vice-President for Personnel Management and Administrative Matters; Yulia Sobakina, Vice-President for Commerce and Marketing; Tatiana Albaut, PR Director were also included into this competent rating.
07 March 2018
Russian pharmaceutical company NovaMedica (investment project of Rusnano), Ministry of Industry and Trade of the Russian Federation and Government of the Kaluga Region have concluded Special Investment Contract (SPIC). Denis Manturov, Minister of the Ministry of Industry and Trade, Anatoly Artamonov, Governor of the Kaluga Region, and Alexander Kuzin, General Director of NovaMedica, signed the contract. Arkady Dvorkovich, Deputy Chairman of the Government of the Russian Federation, and Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO”, were present during the ceremony. SPIC envisages creation of a greenfield facility for manufacturing of sterile injectable dosage forms in the Kaluga region. During its implementation NovaMedica will invest more than three billion Rubles in the creation of the facility. Today this SPIC is the biggest one in the Russian pharmaceutical industry in terms of the amount of investments.
26 December 2017
Russian pharmaceutical company NovaMedica, investment project of Rusnano, informed about receipt of conclusion of the Ministry of Industry and Trade of the Russian Federation over compliance of the facility of the R&D Center of NovaMedica Innotech (subsidiary of NovaMedica) with the Russian standards of the Good Manufacturing Practice (GMP). The certificate issued basing on the integrated audit of the MIT RF commission, proves that the processes of development, manufacturing and quality control at NovaMedica Innotech are organized in accordance with the high standards of quality and manufacturing of tablets, soft and hard gelatin capsules and pellets at its manufacturing facilities meet the Russian GMP requirements.
30 May 2017
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
19 April 2017
NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.
23 December 2016
Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.
13 July 2016
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region.
06 July 2020
06 July 2020
03 July 2020
03 July 2020